| Literature DB >> 30151069 |
Ya-Dan Wen1,2,3, Hong Wang3,4, Yi-Zhun Zhu3,5.
Abstract
The recognition of hydrogen sulfide (H2S) has been evolved from a toxic gas to a physiological mediator, exhibiting properties similar to NO and CO. On the one hand, H2S is produced from L-cysteine by enzymes of cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS), 3-mercaptopyruvate sulfurtransferase (3MST) in combination with aspartate aminotransferase (AAT) (also called as cysteine aminotransferase, CAT); on the other hand, H2S is produced from D-cysteine by enzymes of D-amino acid oxidase (DAO). Besides sulfide salt, several sulfide-releasing compounds have been synthesized, including organosulfur compounds, Lawesson's reagent and analogs, and plant-derived natural products. Based on garlic extractions, we synthesized S-propargyl-L-cysteine (SPRC) and its analogs to contribute our endeavors on drug development of sulfide-containing compounds. A multitude of evidences has presented H2S is widely involved in the roles of physiological and pathological process, including hypertension, atherosclerosis, angiogenesis, and myocardial infarcts. This review summarizes current sulfide compounds, available H2S measurements, and potential molecular mechanisms involved in cardioprotections to help researchers develop further applications and therapeutically drugs.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30151069 PMCID: PMC6087600 DOI: 10.1155/2018/4010395
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Comparison of nitric oxide, carbon monoxide, and hydrogen sulfide.
| Nitric oxide | Carbon monoxide | Hydrogen sulfide | |
|---|---|---|---|
| Formula | NO | CO | H2S |
| Color and odor | Colorless; a mild, sweet odor | Colorless; odorless | Colorless; smell like rotten egg |
| Free radical | Yes | No | No |
| Flammable | No | No | Yes |
| Toxicity | Yes | Yes | Yes |
| Inhibition of mitochondrial cytochrome c oxidase | Yes | Yes | Yes |
| Resources | L-arginine or nitrite | Protohaem IX | L/D-cysteine |
| Intermediate products | L-NG hydroxyarginine, citrulline | Biliverdin IX- | Cystathionine, L-cysteine, |
| Enzymes | eNOS, iNOS, and nNOS | HO-1, HO-2, and HO-3 | CBS, CSE, 3MST/AAT, and DAO |
| Vascular effect | Vasodilation, angiogenesis | Vasodilation, angiogenesis | Vasodilation, angiogenesis |
| Inhibition inflammation | Yes | Yes | Yes |
| Antiapoptosis | Yes | Yes | Yes |
| Haem effect | Yes | Yes | Yes |
| Molecular targets | Soluble guanylate cyclase (sGC) | Soluble guanylate cyclase (sGC) | KATP (ATP-gated potassium) channel |
| Targeting outcome | Increase cGMP, activate KCa channels and nitrosylation | Increase cGMP, activate KCa channels | Increase cGMP and cAMP, activate KATP channels and sulfhydration |
| Application on human | Pulmonary hypertension, lung transplantation, and ARDS | Not available | Not available |
Figure 1Synthesis and catabolism of H2S. AAT: aspartate aminotransferase; CDO: cysteine dioxygenase; CSE: cystathionine γ-lyase; HDH: hypotaurine dehydrogenase; GCS: γ-glutamyl cysteine synthase; GS: glutathione synthase; MAT: methionine adenosyltransferase; MS: methionine synthase; S0: elemental sulfur; SAM: S-adenosylmethionine; THF: tetrahydrofolate; TSST: thiosulfate sulfurtransferase; CBS: cystathionine β-synthase; CSD: sulfinate decarboxylase; DAO: D-amino acid oxidase; H2S: hydrogen sulfide; GNMT: glycine N-methyltransferase; GSH: glutathione; 3MST: 3-mercaptopyruvate sulfide transferase; MTHFR: methylenetetrahydrofolate reductase; SAH: S-adenosylhomocysteine; SO: sulfite oxidase; TSR: thiosulfate reductase; TSMT: thiol S-methyltransferase.
Characteristics of H2S-producing enzymes.
| Cystathionine | Cystathionine | |
|---|---|---|
| Localization | Liver, heart, vessels, kidney, brain, adipose, small intestine, stomach, uterus, placenta, and pancreatic islets | Brain, liver, kidney and ileum, uterus, placenta, and pancreatic islets |
| Activators | Pyridoxal 5′-phosphate | Pyridoxal 5′-phosphate, S-adenosyl-L-methionine, and Ca2+/calmodulin |
| Inhibitors | D,L-propargylglycine, | Hydroxylamine, aminooxyacetate |
| Functional roles | H2S production in the liver and smooth muscle | H2S production in the brain and nervous system |
Figure 2Structures of H2S-releasing molecules.
H2S-releasing compounds used in basic scientific researches.
| Compounds | Constituents | Effects on research fields |
|---|---|---|
| SAC | S-allylcysteine | Protection on cardiovascular and neural systems |
| SPRC | S-propargyl-cysteine | Anticancer, anti-inflammation, and antihypoxic/ischemia and impairs cognition and A |
| GYY4137 | Morpholin-4-ium-4-methoxyphenyl (morpholino) phosphinodithioate | Antagonizes endotoxic shock though anti-inflammatory effects |
| ACS-6 | A H2S-donating sildenafil | Inhibits superoxide formation and gp91phox expression in porcine PAECs |
| ACS-14 | A H2S-releasing aspirin | Regulates redox imbalance, such as GSH formation, HO-1 promoter activity, and isoprostane suppression |
| ACS-15 | A H2S-releasing derivative of diclofenac | Arthritis |
| ACS-67 | A H2S-releasing derivative of latanoprost acid | Glaucoma; retinal ischemia |
| ATB-284 | A H2S-releasing derivative of trimebutine | Irritable bowel syndrome |
| ATB-337 | A H2S-releasing derivative of diclofenac | Gastrointestinal damage induced by NSAIDs |
| ATB-346 | A H2S-releasing derivative of naproxen | Acute and chronic joint pain |
| ATB-429 | A H2S-releasing derivative of mesalamine | Inflammatory bowel disease and antinociceptive and anti-inflammatory effects |
| IK 1001 | Calcium-cross-linked alginate polymer | Suspended animation, multiple hypoxic/ischemic conditions, cardiac remodeling, and congestive heart failure |
Figure 3The chemical structures of SAC, SPC, and SPRC.
Figure 4The equation of spectrophotometric method of H2S.
Figure 5The ranges or limits of H2S measurements.
Figure 6Schematic illustration of molecular mechanisms underlying H2S-induced cardioprotection.